Endobronchial Valve System Now Approved in US for Treatment of Severe Emphysema

Endobronchial Valve System Now Approved in US for Treatment of Severe Emphysema

The U.S. Food and Drug Administration has approved OlympusSpiration Valve System (SVS) as a minimally invasive treatment for severe emphysema, a progressive form of chronic obstructive pulmonary disease (COPD).

The approval is based on positive results from the EMPROVE clinical trial (NCT01812447), which showed meaningful improvements in lung function and quality of life in emphysema patients treated with SVS.

In emphysema, the walls of the alveoli (the small sacs where gas exchanges occur in the lungs) break down, resulting in a loss of the natural recoil of the lungs. With each inhaled breath, air gets trapped in the diseased portions of the lungs, leading to hyperinflation. In hyperinflated lungs, trapped air compresses healthier lung tissue and flattens the diaphragm, making it difficult to breathe.

Minimally invasive endobronchial valves are now recommended for the treatment of severe emphysema over more invasive options, such as lung volume reduction surgery. 

The risk-benefit assessment of the SVS procedure was favorable, with a short procedure time. This is believed to reduce the risk of adverse events such as COPD exacerbations, air leak (pneumothorax), pneumonia, and death.

The SVS consists of many small, umbrella-like devices, placed in the airways to block airflow to the diseased portions of the lungs, redirecting air to healthier lung tissues. The valves expand and contract with breathing, obstructing the targeted lung areas, but permitting trapped air and fluids to escape from the diseased portions. This reduces hyperinflation, allowing healthier lung tissue to expand and making it easier to breathe.

SVS valves are inserted through a flexible bronchoscope in a procedure that is considered minimally invasive. The doctor will first use calibrated balloons to measure the diseased airways and select valves of the right size.

“In the patients I treated [with SVS] in the EMPROVE trial, the most important outcome was a marked reduction in shortness of breath, or dyspnea,” Gerard Criner, MD, founding chair of the department of thoracic medicine and surgery at the Lewis Katz School of Medicine at Temple University, said in a press release.

“This resulted in improved quality of life and patient satisfaction. Dyspnea is the most common symptom in patients with advanced emphysema and severe hyperinflation and is the most refractory to medical treatment,” Criner added.

SVS also received FDA designation as a breakthrough medical device, and was granted priority review status, based on its potential to treat emphysema, a debilitating disease, and its benefits over existing legally marketed alternatives. It is now approved for use in the U.S., EU, Australia, and New Zealand.

According to the manufacturer, patients most likely to benefit from SVS have heterogenous emphysema, which affects localized portions of the lungs.

Alberto Molano was born in Bogotá, Colombia. He studied medicine at Universidad del Rosario and obtained a Ph.D. in Immunology from Weill Cornell Graduate School of Medical Sciences in New York. He conducted research and authored or co-authored twenty publications on molecular and cellular immunology, autoimmunity, immunology of aging and parasite immunology.
×
Alberto Molano was born in Bogotá, Colombia. He studied medicine at Universidad del Rosario and obtained a Ph.D. in Immunology from Weill Cornell Graduate School of Medical Sciences in New York. He conducted research and authored or co-authored twenty publications on molecular and cellular immunology, autoimmunity, immunology of aging and parasite immunology.
Latest Posts
  • COPD, sleep apnea
  • treating emphysema
  • Azithromycin
  • Carrot Rewards
Print Friendly, PDF & Email

11 comments

  1. frederick g. stehle says:

    when will this endobroncial valve system be available to the copd inflicted population and are there going to be centers in the U.S.A. that evaluate candidates? What are the criteria for determining a good vs. bad candidate?

    • Alberto Molano says:

      The valve system is already FDA approved, so I would suggest asking a physician, or alternatively, contacting the manufacturer through their webpage: https://medical.olympusamerica.com/products/spiration-valve-system-treatment-severe-emphysema
      According to the manufacturer, patients most likely to benefit from SVS have emphysema that is not homogenously distributed but affects localized portions of their lungs (heterogenous emphysema). In addition, the lung fissures should separate the diseased portion from the healthy lung tissue completely and no collateral channels of communication should exist between them.

    • Wayne D Peterson says:

      It is available now. I was the first one to receive the endobroncial valve on 3/14/2019 at St. Mary’s Hospital through Mayo Clinic Health system In Rochester, Minnesota.

  2. William Dykes says:

    What are the projected costs for the devices and procedure?
    Are there needs for more than one device to be implanted in one lung?
    What are the likelihoods of Medicare and Medicaid, respectively, covering the costs?

  3. Selena Hill says:

    I have been sick with bronchitis and a sinus infection for about 6 to 7 weeks now. I have been to the doctors twice and the emergency room. I have been put on three different antibiotics, prednisone, an albuterol inhaler, and I take herbal health remedies foundation OTC cold medications. I am no longer coughing a lot and have terrible coughing fits. Then I sound like someone with emphysema. I will cough until I throw up but the doctors don’t really have any new treatments for me, after trying out herbal health remedies foundation now am better. Contact: [email protected] com

Leave a Comment

Your email address will not be published. Required fields are marked *